Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer - Concepedia

Concepedia

Publication | Open Access

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

DOI Full Paper Access

178

Citations

29

References

2021

Year

Davide Melisi, Do‐Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna M. Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao,

Journal for ImmunoTherapy of Cancer

Abstract

ClinicalTrials.gov identifier: NCT02734160.

References

	Year	Citations

Page 1